Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01455220 · ClinicalTrials.gov registry record · NA
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
A NA study, sponsored by University of South Florida.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT01455220 is a NA study that has completed, run by University of South Florida. The registered enrollment target is 45 participants.
The verdict
NCT01455220, a NA study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if sexual dysfunction symptoms and quality of life measures in patients with Multiple Sclerosis may be improved in patients that are prescribed Tysabri.
Interventions
- DRUG Tysabri ® (Natalizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01455220
The ClinicalTrials.gov registry entry for NCT01455220 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tysabri ® (Natalizumab) is the first listed.
NCT01455220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01455220 about?
NCT01455220 is a clinical study titled "The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis". The purpose of this study is to determine if sexual dysfunction symptoms and quality of life measures in patients with Multiple Sclerosis may be improved in patients that are prescribed Tysabri.
What is the current status of trial NCT01455220?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2011-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01455220?
The interventions under investigation include: Tysabri ® (Natalizumab) (DRUG).
Who is sponsoring clinical trial NCT01455220?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.